Publications by authors named "Jerome Segrestaa"

Claim this Profile
R
Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P modulator ponesimod.
Alexander Treiber, Swen Seeland, Jérôme Segrestaa, Cyrille Lescop, Martin H Bolli

Xenobiotica· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: , Preclinical, and Clinical Data.
Christine Huynh, Swen Seeland, Jerome Segrestaa, Carmela Gnerre, Jens Hogeback

Front Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-species comparison of the metabolism and excretion of selexipag.
Tomohiko Ichikawa, Tetsuhiro Yamada, Alexander Treiber, Carmela Gnerre, Jérôme Segrestaa

Xenobiotica· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
Carmela Gnerre, Jérôme Segrestaa, Swen Seeland, Päivi Äänismaa, Thomas Pfeifer

Xenobiotica· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog.
Alexander Treiber, Tommaso Miraval, Martin H Bolli, Jacques-Alexis Funel, Jerome Segrestaa

Xenobiotica· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.
Richard W D Welford, Magali Vercauteren, Annette Trébaul, Christophe Cattaneo, Doriane Eckert, Jérôme Segrestaa

Sci Rep· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.
Ruben de Kanter, Patricia N Sidharta, Stéphane Delahaye, Carmela Gnerre, Jerome Segrestaa

Clin Pharmacokinet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Priska Kaufmann, Séverine Niglis, Shirin Bruderer, Jérôme Segrestaa, Päivi Äänismaa

Br J Clin Pharmacol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968).
Philippe Risch, Thomas Pfeifer, Jerome Segrestaa, Heinz Fretz, Julien Pothier

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of a biomimetic porphyrin catalytic system by addition of acids.
Jérôme Segrestaa, Philippe Vérité, François Estour, Sabine Ménager, Olivier Lafont

Chem Pharm Bull (Tokyo)· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis